PAGE-4 Inhibitors
PAGE-4 inhibitors encompass a range of chemical compounds that affect different biochemical pathways, ultimately leading to a decrease in the functional activity of PAGE-4. Some of these inhibitors function by obstructing kinase activity, which is critical for phosphorylation events that regulate the signaling cascades PAGE-4 is implicated in. This blockade can result in hindering the phosphorylation-dependent regulation of PAGE-4, thereby inhibiting its function. Additionally, other inhibitors target kinases within the MAPK/ERK and PI3K/AKT pathways, which are known to control various post-translational modifications and protein interactions. By disrupting these pathways, the cellular context in which PAGE-4 operates is altered, potentially decreasing its activity. The targeting of cell cycle regulators like CDKs also serves to modify the cellular environment, imposing a state that can indirectly affect the functionality of PAGE-4.
Further inhibition mechanisms include the modulation of protein degradation systems, such as the ubiquitin-proteasome system and the protein folding machinery within the cell. Compounds that impair these systems can lead to a reduction in PAGE-4 activity through indirect routes, such as the accumulation of misfolded proteins or changes in protein stability. Other inhibitors act on stress response signaling pathways, which could alter PAGE-4's interactions with various proteins, thereby indirectly inhibiting its function. Lastly, the influence on DNA repair processes by some compounds may also extend to PAGE-4 by modifying the cellular response to DNA damage, which can have downstream effects on PAGE-4's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that blocks the phosphorylation activity of various kinases, thereby hindering the signaling cascades that PAGE-4 may be involved in, leading to its functional inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Targets multiple tyrosine protein kinases, which are part of signaling pathways that can regulate the activity of PAGE-4 through phosphorylation events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Src family kinases and c-KIT, affecting downstream signaling that could modulate PAGE-4 activity by altering the phosphorylation status of proteins in associated pathways. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
An MEK1/2 inhibitor that disrupts the MAPK/ERK pathway, which might be involved in post-translational modifications of PAGE-4, potentially reducing its activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
CDK4/6 inhibitor that could lead to cell cycle arrest, indirectly affecting PAGE-4's functional role in the cell by altering the cellular context in which PAGE-4 operates. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can suppress the PI3K/AKT/mTOR pathway, potentially diminishing the functional activity of PAGE-4 through indirect effects on protein synthesis and degradation pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that may cause the accumulation of misfolded proteins, indirectly leading to decreased functional activity of PAGE-4 by stressing associated protein folding mechanisms. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modulates the degradation of various proteins via the ubiquitin-proteasome system, which could indirectly decrease the functional activity of PAGE-4 through altered protein stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, potentially preventing the activation of downstream AKT, which could indirectly lead to the inhibition of PAGE-4 by modifying signaling pathways that regulate PAGE-4 activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Inhibits MEK and may disrupt the MAPK/ERK signaling pathway, potentially leading to decreased functional activity of PAGE-4 through effects on its phosphorylation state. | ||||||